Pharmaceuticals

Latest KFF Health News Stories

Sen. Sanders Shows Fire, but Seeks Modest Goals, in His Debut Drug Hearing as Health Chair

KFF Health News Original

The Vermont independent and former presidential candidate was all fire and brimstone at his first hearing on drug prices as head of the Senate HELP Committee. He also pursued a more modest goal of covid vaccine price reductions. It isn’t clear whether Sanders will succeed in even that, but he has put affordability front and center.

KFF Health News' 'What the Health?': The Policy, and Politics, of Medicare Advantage

Podcast

Medicare Advantage, the private plan alternative to traditional Medicare, is embroiled in a growing controversy over whether insurers are being overpaid and what it would mean to reduce those payments. Meanwhile, even as maternal mortality in the U.S. continues to rise, providers of care to pregnant women say they’re leaving states with abortion bans that prevent them from treating pregnancy complications. Margot Sanger-Katz of The New York Times, Jessie Hellmann of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN’s chief Washington correspondent Julie Rovner to discuss these issues and more.

Judge Signals He Could Rule to Halt Sales of Common Abortion Pill

KFF Health News Original

A U.S. District Court case is being widely followed because the judge’s decision could overturn the FDA’s approval of mifepristone two decades ago. With abortion rights polling well even in red states, anti-abortion activists are increasingly turning to the courts to achieve their aims.

¿Ayudan las nuevas guías sobre opioides a los pacientes con dolor crónico?

KFF Health News Original

Las recomendaciones dejaron a muchos pacientes lidiando con las consecuencias para la salud mental y física de la reducción rápida de la dosis o la suspensión abrupta de los medicamentos que habían estado tomando durante años, lo que conlleva riesgos de abstinencia, depresión e incluso suicidio.

New CDC Opioid Guidelines: Too Little, Too Late for Chronic Pain Patients?

KFF Health News Original

In November, the Centers for Disease Control and Prevention released new guidelines for prescribing opioids for pain, allowing physicians more flexibility. But doctors, patients, and advocates wonder if the updated standards will be too little, too late to help chronic pain patients in a country still focused on fighting the ongoing opioid crisis.

KFF Health News' 'What the Health?': Biden Budget Touches All the Bases

Podcast

Very little in the proposed budget released by the Biden administration is likely to become law, particularly with Republicans in charge of the U.S. House. Still, the document is an important statement of the president’s policy priorities, and it’s clear health programs are among those he feels are important. Meanwhile, five women who were denied abortions when their pregnancies threatened their lives are suing Texas. Shefali Luthra of The 19th, Victoria Knight of Axios, and Margot Sanger-Katz of The New York Times join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Harris Meyer, who reported and wrote the two latest KHN-NPR “Bill of the Month” features. Both were about families facing unexpected bills following childbirth.

Decisión de Eli Lilly de bajar el precio de su insulina logrará cambios históricos en los costos

KFF Health News Original

Expertos en precios de medicamentos celebraron la noticia de Eli Lilly y otros esfuerzos. Y estas otras iniciativas para llevar al mercado insulina de menor costo, a su vez, presionarían a Eli Lilly para que mantuviera sus precios bajos.

Eli Lilly Slashed Insulin Prices. This Starts a Race to the Bottom.

KFF Health News Original

Eli Lilly’s news that it plans to cut insulin costs for patients will help, not hinder, the recent efforts in California and by entrepreneurs such as Mark Cuban to offer lower-cost alternatives, drug pricing experts said.

One Texas Judge Will Decide Fate of Abortion Pill Used by Millions of American Women

KFF Health News Original

“What happens in Texas doesn’t stay in Texas,” warns an abortion rights advocate bracing for a district judge’s ruling on whether the abortion pill mifepristone was properly authorized by the FDA. His decision could force the medication off the U.S. market.

A Bitter Battle Over the ‘Orphan Drug’ Program Leaves Patients’ Pocketbooks at Risk

KFF Health News Original

Patients who depend upon special drugs to treat rare diseases are caught in the crossfire as drugmakers and the FDA battle over regulations that reward companies for developing treatments for relatively small pools of patients.

KFF Health News' 'What the Health?': The Kids Are Not OK

Podcast

A new survey from the Centers for Disease Control and Prevention finds that teenagers, particularly girls, are reporting all-time high rates of violence and profound mental distress. Meanwhile, both sides in the abortion debate are anxiously waiting for a district court decision in Texas that could effectively revoke the FDA’s 22-year-old approval of the abortion pill mifepristone. Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN’s chief Washington correspondent, Julie Rovner, to discuss these issues and more.